Literature DB >> 21699388

Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia.

Loic Ysebaert1, Jean-Jacques Fournié.   

Abstract

Here, we examined both genetic and phenotypic determinants of nurse-like cells (NLCs) to better predict their putative functions in chronic lymphocytic leukemia (CLL). We showed that NLCs belong to the wound-healing macrophage subset (so-called 'M2 subset'), but most of all, unsupervised clustering analysis positions NLCs as CLL-specific tumor associated macrophages (TAMs). Chemokinome assays confirmed that NLCs secrete prototypical M2 cytokines and chemokines. Extending previous reports of fludarabine resistance, NLCs are able to promote multidrug resistance. Altogether, we propose that NLCs are not just nursing, but actively participate in the setting of an environment-mediated drug resistance (EM-DR) and immune escape for CLL cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21699388     DOI: 10.3109/10428194.2011.568078

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  20 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Authors:  Paolo Giannoni; Gabriella Pietra; Giorgia Travaini; Rodolfo Quarto; Genti Shyti; Roberto Benelli; Laura Ottaggio; Maria Cristina Mingari; Simona Zupo; Giovanna Cutrona; Ivana Pierri; Enrico Balleari; Alessandra Pattarozzi; Marco Calvaruso; Claudio Tripodo; Manlio Ferrarini; Daniela de Totero
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 9.941

Review 3.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

4.  Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.

Authors:  Marie Tosolini; Christelle Algans; Frédéric Pont; Bernard Ycart; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

5.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

6.  Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia.

Authors:  Avery Polk; Ye Lu; Tianjiao Wang; Erlene Seymour; Nathanael G Bailey; Jack W Singer; Philip S Boonstra; Megan S Lim; Sami Malek; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2016-06-22       Impact factor: 12.531

7.  Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.

Authors:  B S Hanna; F McClanahan; H Yazdanparast; N Zaborsky; V Kalter; P M Rößner; A Benner; C Dürr; A Egle; J G Gribben; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2015-11-02       Impact factor: 11.528

8.  Reprogramming Nurse-like Cells with Interferon γ to Interrupt Chronic Lymphocytic Leukemia Cell Survival.

Authors:  Shalini Gautam; Kavin Fatehchand; Saranya Elavazhagan; Brenda F Reader; Li Ren; Xiaokui Mo; John C Byrd; Susheela Tridandapani; Jonathan P Butchar
Journal:  J Biol Chem       Date:  2016-05-13       Impact factor: 5.157

Review 9.  'Trained immunity': consequences for lymphoid malignancies.

Authors:  Wendy B C Stevens; Mihai G Netea; Arnon P Kater; Walter J F M van der Velden
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

Review 10.  Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.

Authors:  Rossana Maffei; Stefania Fiorcari; Silvia Martinelli; Leonardo Potenza; Mario Luppi; Roberto Marasca
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.